We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tern Plc | LSE:TERN | London | Ordinary Share | GB00BFPMV798 | ORD 0.02P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 4.76% | 4.40 | 4.30 | 4.50 | 4.55 | 4.20 | 4.20 | 5,092,727 | 09:06:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 66k | -10.45M | -0.0269 | -1.64 | 17.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/1/2019 09:42 | Brexit!!!!! :-(((((((((((((((((( | lntermaie | |
31/1/2019 09:42 | Could be this one - the largest; Used on me for prostatectomie- The da Vinci Surgical System is a robotic surgical system made by the American company Intuitive Surgical. Approved by the Food and Drug Administration (FDA) in 2000, it is designed to facilitate complex surgery using a minimally invasive approach, and is controlled by a surgeon from a console. The system is commonly used for prostatectomies, and increasingly for cardiac valve repair and gynecologic surgical procedures.[1][2] According to the manufacturer, the da Vinci System is called "da Vinci" in part because Leonardo da Vinci's "study of human anatomy eventually led to the design of the first known robot in history."[3] Da Vinci Surgical Systems operate in hospitals worldwide, with an estimated 200,000 surgeries conducted in 2012, most commonly for hysterectomies and prostate removals.[4] As of September 30, 2017, there was an installed base of 4,271 units worldwide – 2,770 in the United States, 719 in Europe, 561 in Asia, and 221 in the rest of the world.[5] The "Si" version of the system costs on average slightly under US$2 million, in addition to several hundred thousand dollars of annual maintenance fees.[6] | philjeans | |
31/1/2019 09:42 | And such a looseeeeeeer :-(((((((((((((((((( | lntermaie | |
31/1/2019 09:42 | a better read of it. | still waiting | |
31/1/2019 09:42 | Am so sad :-(((((((((((((((( | lntermaie | |
31/1/2019 09:42 | It is old news of a pitifully low value contract. No wonder the numpties are buying into it. 12p today or tomorrow? | jonc | |
31/1/2019 09:42 | Here we go RNS flood gates opened for 2019... | 78steve | |
31/1/2019 09:42 | andrbea - you beat me to it - I liked that bit as well | upthegardenpath | |
31/1/2019 09:42 | The milestone trigger is still to come imo. More bad news for shorters. | johnb5 | |
31/1/2019 09:41 | I think the milestone will different. | warrenfingerfood | |
31/1/2019 09:40 | The Feb 19 webinar with nCipher will elaborate on this news, for sure. | andrbea | |
31/1/2019 09:39 | Is this the milestone trigger ? | still waiting | |
31/1/2019 09:39 | I loose again. Very loose. | lntermaie | |
31/1/2019 09:39 | Kiss me? :-(((((((((((((((((( | lntermaie | |
31/1/2019 09:39 | Duxy and his crew are royally F...ked | johnma | |
31/1/2019 09:38 | I am so sad :-(((((((((((((((((( | lntermaie | |
31/1/2019 09:38 | I wonder if ncipher might be a candidate to buy DA now ? | still waiting | |
31/1/2019 09:38 | It doesn’t take much to unravel days of shorters postings does it and this was just an update. Tick tock. | warrenfingerfood | |
31/1/2019 09:38 | The first of many medical device contracts from this partnership. Thales/Ncipher carry a lot of weight in the cyber market. Tern ready to open the taps! | tyrano1 | |
31/1/2019 09:37 | That's better. We are excited to secure this long-term contract alongside our strategic partner nCipher and look forward to many more,” said Darron Antill, CEO of Device Authority. | andrbea | |
31/1/2019 09:37 | And I am having my hair done :-)))))))))))))))) | lntermaie | |
31/1/2019 09:36 | What's occurring on 29th March??????????????? | lntermaie |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions